asikreba 12,5 mg kapsułki twarde
zentiva, k.s. - sunitinib malate - kapsułki twarde - 12,5 mg
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Środki przeciwnowotworowe - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitynib adamed 37,5 mg kapsułki twarde
adamed pharma s.a. - sunitynibu jabłaczan - kapsułki twarde - 37,5 mg
sunitynib adamed 25 mg kapsułki twarde
adamed pharma s.a. - sunitynibu jabłaczan - kapsułki twarde - 25 mg
sunitynib adamed 12,5 mg kapsułki twarde
adamed pharma s.a. - sunitynibu jabłaczan - kapsułki twarde - 12,5 mg
sunitynib adamed 50 mg kapsułki twarde
adamed pharma s.a. - sunitynibu jabłaczan - kapsułki twarde - 50 mg
asikreba 50 mg kapsułki twarde
zentiva, k.s. - sunitynibu jabłaczan - kapsułki twarde - 50 mg
inlyta
pfizer europe ma eeig - aksytynib - rak, komórka nerek - inhibitory białka kinazy - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.